Tubulis GmbH

Booth number 4607-08


Tubulis generates uniquely matched Antibody Drug Conjugates (ADCs) based on proprietary and broadly patent protected next-generation conjugation and linker-payload platforms.

About us

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.

Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.

Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.

Tubulis GmbH
Butenandtstr. 1
81375 Munich

Phone: +49 1723 505125
Internet: www.tubulis.com

Contact person

Ingo Lehrke
Phone: +49 1723 505125

Products and Services


We are currently advancing three ADC assets:

TUB-010 | Lymphoma, pre-IND; ready for partnering

TUB-030 | solid cancer, discovery

TUB-040 | solid cancer, discovery

Strong technology portfolio
Tub-tag and P5 by Tubulis - one company, two unique, complementing ADC conjugation technologies fulfilling the needs of 3rd generation ADCs:

  • ADC Homogeneity leading to mAb-like ADC properties

  • Linker Stability ensuring safe delivery

  • High DAR flexibility enabling unique antibody-payload combinations.

  • Chemical flexibility giving access to novel payload classes

    Focus at this meeting is to explore opportunities for:

    1) Development & commercialization partnerships for TUB-010 our IND-ready ADC for lymphomas, targeting CD30

    2) Pharma partnerships for novel ADCs
    Keywords: CD30, cancer, oncology, ADC, solid tumors, lymphoma, novel linkers & payloads

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection